- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Cancer Detection Breakthrough: Pan-India Study Finds Higher Blood DNA Linked to Stronger Tumour Signals - Video
Overview
One blood test for detecting multiple cancers. Sounds almost too good to be true, doesn't it? Indian researchers have developed a test that uses DNA signals and artificial intelligence to identify possible cancers through a single blood sample.
Called CancerSpot, the test was developed by Bengaluru-based Strand Life Sciences. The findings were published in the Proceedings of the National Academy of Sciences (PNAS).
The four-year study involved 1,480 participants across 43 hospitals in India and evaluated the test in patients with 14 different types of cancer and healthy individuals.
In an independent validation group, the test detected 72% of cancer cases, with a false-positive rate of just 1.4%.
So how does it work? Cells release tiny fragments of DNA into the bloodstream. In people with cancer, some fragments come from tumours and carry distinctive chemical changes known as DNA methylation.
CancerSpot uses DNA sequencing and artificial intelligence to identify these cancer-associated patterns.
Researchers also discovered something unexpected. Higher levels of circulating DNA were associated with stronger cancer signals and better detection, even among patients with cancers at similar stages.
They initially expected DNA released by immune cells to dilute tumour signals. Instead, both appeared to increase together, potentially making cancer easier to detect.
However, the results also mean that some cancers were missed. A positive result would require further medical investigations to establish a diagnosis.
Importantly, the study involved newly diagnosed cancer patients and healthy participants, rather than demonstrating successful screening across the general population.
Researchers stressed that further independent validation across diverse groups and clinical settings is necessary to establish whether the test can improve early diagnosis and patient outcomes.
For now, the findings offer a promising step towards simpler cancer detection, not a replacement for existing screening tests.
REFERENCE: S. Basu, et al.; Rising cell-free DNA level tracks cancer-associated methylation signal and improves multicancer detection, Proc. Natl. Acad. Sci. U.S.A. 123 (45) e2629041123, https://doi.org/10.1073/pnas.2629041123 (2026).


